Purpose: To report the clinical findings of unilateral central toxic keratopathy (CTK) associated with inadvertent exposure to topical minoxidil 5% solution 1 day after bilateral photorefractive keratectomy (PRK).
Methods: Anterior segment slit-lamp photography, anterior segment optical coherence tomography (AS-OCT), pachymetry map, epithelial map, and manifest refractions were recorded.
Results: This is a case of a 27-year-old male who underwent bilateral PRK and presented 5 days after surgery with the complaint of acute decreased visual acuity in the left eye (LE). His LE was reportedly exposed to topical ethanol-based minoxidil 5% on postoperative day 1, which he was using as a posthair transplant treatment. Clinical examination showed hyperopic shift, poor visual acuity, central corneal opacity, epithelial irregularity, central corneal thinning, and flattening on AS-OCT. These findings were consistent with a diagnosis of CTK. The patient was monitored with conservative treatment and demonstrated full recovery after 6 months.
Conclusion: It is recommended to warn patients who have undergone refractive surgery concerning the use of ethanol-containing agents, such as minoxidil solution, because of the possible risk of CTK, a complication not formally recognized.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832464 | PMC |
| http://dx.doi.org/10.4103/joco.joco_342_21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Co-delivery of minoxidil and finasteride via ionic liquid and cyclodextrin-assisted in situ thermosensitive hydrogel for synergistic treatment of androgenic alopecia.
Int J Pharm
January 2025
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 51006 China. Electronic address:
Androgenic alopecia (AGA), the most prevalent type of progressive hair loss, currently lacks an effective topical treatment regimen. In this study, we synthesized an ionic liquid (IL) to co-solubilize minoxidil (MXD) and finasteride (FIN) and subsequently formulated them into an in situ thermosensitive ionic liquid/cyclodextrin/poloxamer hydrogel (ICPG), termed M + F@ICPG. M + F@ICPG was developed for the transdermal co-delivery of these two drugs, aiming to provide a multipath therapeutic approach for AGA while avoiding the adverse effects commonly associated with oral FIN and topical MXD tincture.
View Article and Find Full Text PDFAn update on nanocarriers for follicular-targeted drug delivery for androgenetic alopecia topical treatment.
Expert Opin Drug Deliv
January 2025
Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia (UnB), Brasília, DF, Brazil.
Introduction: Androgenic alopecia is a multifactorial disease with a high incidence and a great psychological burden on patients. The current FDA-approved treatment is topical minoxidil or oral finasteride. However, both present significant limitations.
View Article and Find Full Text PDFInnovating alopecia treatment: nanostructured lipid carriers as advanced delivery platforms.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Faculty of Pharmacy, Integral University, Lucknow, 226026, India.
Alopecia, a common dermatological condition, poses significant psychological and social challenges. Despite the availability of various treatments, their efficacy is often limited by poor bioavailability and delivery challenges. Nanostructured lipid carriers have emerged as promising advanced drug delivery systems for alopecia treatment due to their ability to encapsulate both hydrophilic and lipophilic compounds, enhancing their stability, solubility, and controlled release.
View Article and Find Full Text PDFFractional CO Laser and Minoxidil in the Treatment of Alopecia Areata, A Comparative Study.
Lasers Surg Med
January 2025
Dermatology, Venereology and Andrology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Background: Alopecia areata (AA) is a chronic inflammatory disease that affects the hair follicles and sometimes the nails. It usually presents as a single or multiple patches of hair loss on the scalp, but any hair-bearing skin can be involved. AA treatment depends on the severity and extent of the disease.
View Article and Find Full Text PDFSublingual Minoxidil Increases Fibre Diameter in Male Androgenetic Alopecia. - A proxy for Reversal of Hair Follicle Miniaturization.
Clin Exp Dermatol
January 2025
Tricholab AB, Warsaw, Poland.
Background: The histological hallmark of male androgenetic alopecia (MAGA) is transformation of terminal follicles into miniaturized secondary-vellus follicles. As the volume of the dermal papilla determines the size of the hair bulb and hair fibre diameter, any treatment induced increase in fibre diameter could be used as a proxy for reversal of hair follicle miniaturization. While clinical trials with minoxidil topical solution in MAGA do not demonstrate increased fibre diameter, vellus-to-terminal reconversion is shown in a humanized mouse model treated with MXL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!